media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Tigermed to Privatize Frontage at HK$2.37 per Share, a ~59.1% Premium, and Divest Overseas Lab Business

After trading hours on November 9, 2026, Tigermed (300347.SZ; 03347.HK) announced that it intends to sell its controlling interest in subsidiary Frontage Holdings (01521.HK) and divest its overseas laboratory services business. The transaction comprises a privatization and a separation. Its wholly owned subsidiary Hongkong Tigermed, together with CRL and Dr. Li Song, established SanRex as the acquisition vehicle to privatize Frontage by way of a scheme of arrangement. SanRex is a consortium in which Tigermed holds a 53.4% stake. The cancellation price is HK$2.37 per scheme share, representing a premium of approximately 59.1% over Frontage’s closing price of HK$1.49 on the preceding trading day. Upon completion of the privatization, Frontage will become a wholly owned subsidiary of SanRex and its listing will be withdrawn from the Hong Kong Stock Exchange. The privatization will be followed by a separation: consortium member CRL (Charles River Laboratories, NYSE: CRL) will hold Frontage’s target ...
- Source: drugdu
- 47
- November 10, 2026
argenx to Acquire Unnatural Products for Up to Approximately $1.15 Billion, Adding Peptide Discovery Engine

AMSTERDAM, the Netherlands, Nov. 9, 2026 — argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, announced a definitive agreement to acquire Unnatural Products (UNP), adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. argenx, which already holds a minority stake in UNP, will acquire all remaining shares in a transaction valuing UNP at up to approximately $1.15 billion across upfront and milestone payments. The acquisition expands the ways argenx can pursue novel biology and develop oral or long-acting medicines for people living with serious immune-mediated diseases. Karen Massey, CEO of argenx, said UNP’s macrocyclic peptide capabilities are highly complementary to the company’s antibody engineering and create new possibilities for oral and long-acting medicines, adding that after more than two years of collaboration, argenx will preserve UNP’s science-first, entrepreneurial and patient-focused way of working. Under the terms, argenx will pay an upfront payment of $550 million in cash ...
- Source: drugdu
- 45
- November 10, 2026
Henlius’s HLX11 Approved in Brazil as the Country’s First Pertuzumab Biosimilar

Recently, Henlius, a controlling subsidiary of Fosun Pharma, and Organon jointly announced that HLX11, a pertuzumab biosimilar independently developed by Henlius and commercialized by Organon outside China, has received marketing approval from Brazil’s National Health Surveillance Agency (ANVISA) for patients with HER2-positive breast cancer, making it the first pertuzumab biosimilar approved in Brazil. Henlius has out-licensed the product’s commercialization rights outside China to Organon. HLX11 is administered by intravenous infusion in combination with trastuzumab and docetaxel for patients with HER2-positive, metastatic or unresectable locally recurrent breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. In combination with trastuzumab and chemotherapy, it is also indicated for neoadjuvant treatment of HER2-positive locally advanced, inflammatory or early-stage breast cancer (tumor >2 cm or node-positive), and for adjuvant treatment of HER2-positive early-stage breast cancer at high risk of recurrence. HER2-positive breast cancer accounts for approximately 15% to 20% of ...
- Source: drugdu
- 41
- November 10, 2026
Lunan Pharmaceutical’s Shuerte® Thioctic Acid Tablets have been approved for marketing!

Recently, Shuerte® Thioctic Acid Tablets (specification: 0.6g) of Shandong New Era Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group , were approved for marketing by the National Medical Products Administration and are regarded as having passed the consistency evaluation of generic drug quality and efficacy. Approval number: National Drug Approval Number H20266515. This product is indicated for sensory abnormalities caused by diabetic peripheral neuropathy. Lipoic acid is a B vitamin and a coenzyme for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase systems. In vitro studies show that lipoic acid can reduce lipid oxidation in nerve tissue and inhibit protein glycosylation and aldose reductase. In vivo, lipoic acid has antioxidant activity and participates in the recycling of antioxidants such as glutathione and coenzyme Q10. This product is rapidly absorbed after oral administration. Due to a significant first-pass effect, the absolute bioavailability (compared to intravenous injection) is approximately 20%, and the plasma half-life ...
- Source: drugdu
- 40
- November 10, 2026
$455 million! Boston Scientific ramps up its investment in heart pumps.

According to recent foreign media reports, Blackstone Life Sciences has signed a $455 million collaboration agreement with Boston Scientific to jointly fund the development of Boston Scientific’s next-generation micro heart pump system. It is understood that Boston Scientific’s next-generation micro heart pump system is part of the Vitalyst Temporary Percutaneous Transvalvular Circulatory Support System project. This device is designed to increase cardiac output, improve blood flow, and treat cardiogenic shock caused by acute myocardial infarction. Cardiogenic shock is a life-threatening condition in which the heart is unable to pump enough blood to supply the brain and other organs, manifesting as a heart attack or other heart problems. Despite advancements in treatment, its mortality rate remains high. According to Blackstone, the Vitalyst system was developed to address core unmet needs of critically ill cardiogenic patients, with the goal of improving efficacy, safety, and ease of use for physicians treating these patients. ...
- Source: drugdu
- 44
- November 10, 2026
Children’s cold medicine launched

Recently , Yiling Pharmaceutical issued an announcement stating that the National Medical Products Administration has officially approved the marketing of Lianhua Cold Granules for children, a Class 1.1 new traditional Chinese medicine , with the approval number Z20260006. In terms of indications, Lianhua Cold Granules for Children are mainly used to clear heat and relieve exterior symptoms, and to promote lung function and relieve heat. They are used for children aged 4-12 years with wind-heat colds , characterized by symptoms such as nasal congestion, runny nose with thick nasal discharge, sore throat, cough, headache, red tongue, thin yellow coating, and floating and rapid pulse. This means that it is not a simple reduced-dose version of adult cold medicine, but an innovative traditional Chinese medicine specifically for pediatric children with wind-heat as the main syndrome. In terms of R&D attributes, this product belongs to the innovative traditional Chinese medicine guided by ...
- Source: drugdu
- 40
- November 10, 2026
Ribo Life Science files EU Phase I clinical trial application for dual-target siRNA SR122

On November 10, Ribo Life Science (06938.HK) announced in a voluntary disclosure that it had filed a Phase I clinical trial application in the European Union for its in-house candidate SR122 injection. SR122 is a GalNAc-conjugated small interfering RNA (siRNA) therapy that targets both ApoC3 and PCSK9. It is being developed for dyslipidemia, including severe hypertriglyceridemia and mixed dyslipidemia. The planned Phase I study will be randomized and placebo-controlled. It will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered SR122 in healthy volunteers. Source: https://finance.eastmoney.com/a/202611103926814664.html
- Source: drugdu
- 44
- November 10, 2026
China accepts Shanghai RAAS’s SR604 clinical trial application for Glanzmann thrombasthenia

On November 9, Shanghai RAAS announced that China’s National Medical Products Administration had accepted a clinical trial application for SR604 injection as a prophylactic treatment for Glanzmann thrombasthenia. SR604 is a humanized monoclonal antibody that binds human activated protein C with high affinity and selectively inhibits its anticoagulant activity. For the prevention of bleeding in hemophilia A and B, SR604 met its prespecified primary endpoint in Phase II, and key data were presented at an international conference. Phase III is underway. Studies on the prevention of bleeding in congenital factor VII deficiency and von Willebrand disease are both in Phase II. In a separate public notice, China’s Center for Drug Evaluation proposed including SR604 injection in the extended pilot program supporting innovative drug development for rare diseases. Source: https://finance.eastmoney.com/a/202611093926395123.html
- Source: drugdu
- 38
- November 10, 2026
MEDICA Düsseldorf

Organiser：MEDICA Time：November 16-19, 2026 Address：Ostfach 10 10 06, D-40001 Düsseldorf, Stockum Church Street 61, D-40474, Düsseldorf, Germany – D-40001 Exhibition hall：Düsseldorf Exhibition Center Product range: Medical Equipment‌: Medical electronic instruments, clinical laboratory analysis instruments, dental equipment and materials, hemodialysis equipment, respiratory equipment, hospital ward equipment, operating room equipment, emergency room equipment, hospital office equipment ‌Imaging and Diagnostics‌: Ultrasound instruments, X-ray equipment, medical optical instruments ‌Disposable Consumables‌: Disposable medical supplies, dressings and hygiene materials, surgical instruments ‌Medical Devices‌: Medical health care equipment, home health care products, physical therapy, orthopedic technology ‌Medical Peripherals‌: Information and communication technology, medical services and publications, IT systems and IT solutions About MEDICA Düsseldorf： MEDICA Düsseldorf, Germany is the world’s largest and most authoritative hospital and medical equipment exhibition, ranking first among global medical trade shows with its irreplaceable scale and influence. It is held annually in Düsseldorf, Germany, showcasing a full range of products ...
- Source: drugdu
- 47
- November 10, 2026
【EXPERT Q&A】When overseas buyers contact multiple suppliers simultaneously, is it still necessary for enterprises to invest a lot of time in following up?

Drugdu.com expert’s response: When conducting foreign trade in pharmaceuticals and medical devices, suppliers frequently encounter this scenario: overseas buyers send inquiries asking about product prices, specifications, delivery lead times, and relevant qualifications. After a period of communication, they later discover that the buyer has simultaneously contacted several suppliers, and even explicitly stated that they are comparing quotations and supply terms from different companies. Some suppliers consequently reduce the priority of these inquiries, assuming that since the buyer is reaching out to multiple firms, they may not ultimately select their offer. This is especially true for products like APIs, pharmaceutical excipients, and medical equipment, where preparing quotations, COAs, specifications, and other technical documentation takes considerable time. If the effort only ends up helping the buyer gather market information, the upfront investment can seem to hold little value. However, in pharmaceutical B2B procurement, it is quite common for buyers to evaluate multiple ...
- Source: drugdu
- 73
- November 9, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.